The service provides chemistry, manufacturing, and controls (CMC) support for biopharmaceutical products, encompassing pharmaceutical development strategy, process development and optimization, formulation and analytical method development, CDMO/CMO selection and oversight, and preparation of CMC content for regulatory submissions across modalities including small molecules, biologics, and advanced therapies. Engagement duration varies with scope and stage, from focused assessments of existing CMC packages to longer-running support through process scale-up and validation, regulatory interactions, and preparation for commercial manufacturing. Support is aimed primarily at emerging biopharmaceutical companies who need robust, modality-specific CMC input to progress assets or evaluate opportunities. The goal is to ensure that manufacturing strategies, control frameworks, and supply chains are fit for purpose at each development stage, de-risking regulatory review and enabling reliable, compliant supply from early clinical studies through to commercial launch. Activities typically include expert review of current CMC and manufacturing documentation, identification of gaps against regulatory expectations, development of risk-mitigated CMC plans, vendor and technology transfer support, and quality and supply chain planning aligned with both FDA and EMA requirements. Deliverables are usually provided as structured written reports and slide decks, supplemented by working sessions and video conferences to stress-test options, align stakeholders, and refine decisions. The expected outcome is that clients gain a clear, actionable view of their CMC and manufacturing needs, realistic timelines and resource requirements, and a practical roadmap for advancing manufacturing readiness in parallel with clinical and regulatory milestones. Support is delivered primarily online through document exchange and virtual meetings, enabling rapid access to specialists with directly relevant manufacturing and CMC experience.